A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.

Trial Details

NCT ID
NCT06494371
Phase
PHASE1
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • LCAR-HL30 cells
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects voluntarily participate in clinical research.
  • Aged 18 to 75 years, either sex.
  • Eastern Cooperative Oncology Group (ECOG) score 0-1 (Dose escalation phase). ECOG score 0-2 (Dose expansion period).
  • Histologically confirmed Hodgkin's lymphoma or Anaplastic large cell lymphoma with positive CD30 expression.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →